Table 2.

Multivariable analysis of predictors of antibody response at 3 ± 1 months after first dose administration of mRNA COVID-19 vaccine in SOT recipients.

Variable	OR (95% CI)	p-Value (α = 0.05)
Sex	-	-
Male	1 (ref)	-
Female	0.91 (0.67 1.24)	0.568
Age	-	-
Categorical increase (<39 y; 40–49 y; 50–59 y; 60–69 y; ≥70 y)	0.67 (0.60 0.76)	<0.001
Type of graft	-	-
Kidney	1 (ref)
Heart	0.64 (0.39 1.07)	0.090
Liver	2.71 (1.55 4.72)	<0.001
Lung	1.16 (0.46 2.95)	0.750
Time from transplant to vaccination	-	-
Less than 1 year	1 (ref)
1 to 3 years	1.79 (0.87 3.67)	0.111
More than 3 years	4.92 (2.56 9.45)	0.000
Time from vaccination onset to serological assessment
Categorical increase (40–70 d; 70–100 d; 100–130 d; 130–160 d; >160 d)	1.30 (1.10 1.53)	<0.001
Comorbidities
No	1 (ref)
Yes	0.60 (0.43 0.83)	0.002
Type of vaccine
BNT162b2	1 (ref)
mRNA-1273	3.57 (2.25 5.67)	<0.001
Immunosuppressive drugs at the time of vaccination
Cyclosporine	0.71 (0.30 1.67)	0.429
Tacrolimus	0.52 (0.23 1.16)	0.111
Azathioprine	3.43 (1.20 9.82)	0.022
Mycophenolates	0.29 (0.20 0.43)	<0.001
Sirolimus	0.70 (0.18 2.66)	0.598
Everolimus	0.72 (0.43 1.20)	0.212
Steroids	0.44 (0.30 0.65)	0.000
Impaired graft function
Good	1 (ref)
Impaired, Failure, and others	0.38 (0.26 0.55)	<0.001

OR: odd ratio.